 |
|
Failure to Report Financial Disclosure Information
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: We would like to apologize to the readers and editors of JAMA for a difference in understanding of the JAMA policy for reporting financial disclosures and resultant failure to report our disclosure information in our article.1 The basis of our omission of financial information was that we did not foresee a reasonable likelihood of financial gain or bias as a consequence of our activities or employment in other areas of the fields of prostate cancer or cancer research that were separate from our study in early stage prostate cancer and, therefore, did not believe that there were additional relevant disclosures.
In the interest of full transparency and to avoid any potential misunderstanding, we hereby report that during the past 5 years, including during the time the study was conducted and the manuscript was submitted to JAMA, Dr Siu-Long Yao has been employed by Sanofi-Aventis and Schering-Plough . . . [Full Text of this Article]
Grace Lu-Yao, MPH, PhD
Robert Wood Johnson Medical School
New Brunswick, New Jersey
Peter Albertsen, MD
University of Connecticut
Farmington
Weichung Shih, PhD
University of Medicine and Dentistry of New Jersey
Piscataway
Siu-Long Yao, MD
syao@aya.yale.edu
Robert Wood Johnson Medical School
New Brunswick
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Survival Following Primary Androgen Deprivation Therapy Among Men With Localized Prostate Cancer
Grace L. Lu-Yao, Peter C. Albertsen, Dirk F. Moore, Weichung Shih, Yong Lin, Robert S. DiPaola, and Siu-Long Yao
JAMA. 2008;300(2):173-181.
ABSTRACT
| FULL TEXT
|
